<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Lecture 2: Basic & Behavioral Pharmacology</title>
    <link rel="stylesheet" href="styles.css">
</head>
<body>
    <header>
        <h1>Lecture 2: Basic & Behavioral Pharmacology</h1>
        <nav>
            <ul>
                <li><a href="index.html">Home</a></li>
                <li><a href="lecture1.html">Lecture 1</a></li>
                <li><a href="lecture2.html">Lecture 2</a></li>
                <li><a href="lecture3.html">Lecture 3</a></li>
                <li><a href="lecture4.html">Lecture 4</a></li>
                <li><a href="lecture5.html">Lecture 5</a></li>
                <li><a href="lecture6.html">Lecture 6</a></li>
            </ul>
        </nav>
    </header>

    <section id="lecture2">
        <h2>Key Concepts</h2>
        <ul>
<li><strong>Dose-Response Curves:</strong> These curves illustrate the relationship between drug concentration and effect. They help categorize full agonists, partial agonists, and antagonists based on their maximum efficacy and potency.</li>
                <li><strong>Pharmacokinetics (ADME):</strong> Absorption, Distribution, Metabolism, and Excretion (ADME) determine a drug's bioavailability and duration in the body. Factors like liver enzyme activity and renal clearance play pivotal roles.</li>
                <li><strong>Competitive vs. Non-Competitive Antagonists:</strong> Competitive antagonists shift dose-response curves to the right, whereas non-competitive antagonists reduce maximal efficacy without shifting potency.</li>
                <li><strong>Agonist Potency:</strong> Potency is measured by the EC50 (concentration causing 50% maximal effect). Lower EC50 indicates higher potency.</li>
                <li><strong>Inverse Agonists:</strong> These drugs stabilize receptors in their inactive state, reducing activity below baseline levels.</li>
                <li><strong>Behavioral Assays:</strong> Tests like the Tail Flick (pain threshold) and Open Field (anxiety/motor activity) evaluate pharmacological effects on behavior.</li>
                <li><strong>Prodrug Strategies:</strong> Prodrugs improve pharmacological profiles by enhancing solubility or targeting specific tissues for activation.</li>
                <li><strong>First-Pass Metabolism:</strong> Liver metabolism reduces drug bioavailability, necessitating higher oral doses compared to intravenous administration.</li>
                <li><strong>Therapeutic Index (TI):</strong> TI compares the effective dose (ED50) to the lethal dose (LD50), indicating drug safety margins.</li>
                <li><strong>Drug-Drug Interactions:</strong> Enzyme inhibitors or inducers can alter drug metabolism, leading to toxicity or reduced efficacy.</li>
        </ul>
    </section>

    <footer>
        <p>&copy; 2023 Neuropharm Review</p>
    </footer>
</body>
</html>